3Vote!
Business Wire (Free subscription) | 05/11/2009
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that Tim Rothwell, former Chairman of Sanofi-aventis U.S., has been appointed to the Company’s Board of Directors effective immediately. Mr. Rothwell’s appointment fills the vacancy created by Franklin Berger, who recently resigned from the Board in order to focus more time on certain other business...
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 05/11/2009
Sanofi Aventis (NYSE: SNY) closed yesterday at $36.99. So far the stock has hit a 52-week low of $23.95 and 52-week high of $40.17. Sanofi Aventis stock has been showing support around 36.38 and resistance in the 37.66 range. Technical indicators for the stock are Neutral and S&P gives SNY a neutral 3 STAR (out of 5) hold rating. SNY appears on the Investors Observer Analysts Favorites list. For...
3Vote!
Business Wire (Free subscription) | 05/11/2009
PARIS--(BUSINESS WIRE)--Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces today the extension of its knowledge database agreement with sanofi-aventis research & development for an additional three-year term. Under the agreement, Aureus will provide new AurSCOPE® knowledge databases and continue to update existing...
3Vote!
SeekingAlpha ETFs (Free subscription) | 05/11/2009
Mike Havrilla submits: Investors who are bullish on the generic drug industry may consider implementing a 130 / 30 global pharma investing strategy through equal-weight (5% each) short positions for the six brand drug companies outlined below with 30% of their assets while investing 130% of assets in long positions among generic drug makers. The list of brand drug companies with significant patent...
3Vote!
SPICY IP (Free subscription) | 03/11/2009
Even as India and other developing countries are on the verge of filing a formal complaint at the WTO with regard to the 17 highly controversial seizures which have occurred since late last year (which we have posted several times on here ) yet another consignment of drugs has been seized last month on grounds of patent violation, this time in France. The consignment was of 1.74 million pills of the...
Explore : Arabian Peninsula,
Bristol-Myers Squibb,
Doha,
Drug Manufacturers,
European Commission,
Health-Fitness,
Health Industries,
IMS Health Inc.,
India,
Mumbai,
Pharmaceutical Industry,
Qatar,
Software,
Software and services,
Venezuela,
World Trade Organization
3Vote!
Daily Khabor @ Khabor.Com (Free subscription) | 03/11/2009
Shortcut to: http://www.outsourcing-pharma.com/On-your-radar/Globalisation/Bangladesh-a-huge-opportunity-for-growth-CEO Bangladesh a "huge opportunity" for growth; CEO By Nick Taylor, 09-Sep-2009 Related topics: Globalisation , Contract Manufacturing , Bulk ingredients , Drug delivery, formulation , Fill & finish, packaging , Validation services Bangladesh represents a " huge opportunity...
3Vote!
Business Wire (Free subscription) | 03/11/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today reported financial results for the third quarter ended September 30, 2009. “With a number of recent positive product-related updates, including an FDA Advisory Committee on Exalgo and its REMS program, Sanofi-Aventis’ acquisition of Prednisporin, a CombinatoRx-derived combination drug candidate, through its...
3Vote!
Trade Regulation Talk (Free subscription) | 03/11/2009
FTC, Canada Competition Bureau Approve Schering-Plough’s Acquisition of Merck This posting was written by Jeffrey May, Editor of CCH Trade Regulation Reporter. Schering-Plough Corporation can proceed with its proposed $41.1 billion acquisition of Merck & Co. Inc. under the terms of a proposed FTC consent order, according to the agency's October 29 announcement . The consent order would settle...
3Vote!
The Business Courier of Cincinnati (Free subscription) | 02/11/2009
Prasco Laboratories said Monday it has signed sales and distribution agreements with Winthrop U.S., a unit of Sanofi-Aventis U.S. (SNY)
3Vote!
The Huffington Post (Free subscription) | 02/11/2009
A lobbying war between two pharmaceutical companies vying to market a generic blood-thinner has prompted an inquiry by Sen. Chuck Grassley and Senate Finance Committee Chairman Max Baucus, reports the Wall Street Journal. Drug makers Amphastar Pharmaceuticals Inc. and Momenta Pharmaceuticals Inc. both applied to the Food and Drug Administration several years ago to make a generic version of the blood-thinning...
3Vote!
WSJ.com (Free subscription) | 02/11/2009
The Supreme Court Monday rejected a generic-drug maker's appeal challenging a patent for a blood-thinning drug developed by Sanofi-Aventis.
3Vote!
ABC News (Free subscription) | 02/11/2009
Sanofi-Aventis names pharma business head Hanspeter Spek as president of global operations
3Vote!
Seattle Times (Free subscription) | 02/11/2009
French drugmaker Sanofi-Aventis says it is promoting two high-ranking executives and adding a third to its executive committee.
5Vote!
Poverty News Blog (Free subscription) | 02/11/2009
The cost of the anti-malaria drug Artemisinin combination therapy is more than poor people can afford. Researchers are saying that the high cost results in another million deaths a year from malaria. Poor malaria sufferers instead go to an an older, cheaper drug that is not nearly as effective as ACT. From Reuters, reporter Kate Kelland tells us more about the study into malaria drug use. Artemisinin...
3Vote!
Drug and Device Law (Free subscription) | 02/11/2009
We have rules at this blog: We don't criticize drug and device companies, and we don't criticize defense law firms. But we're making an exception here, and we bet you can understand why: Shook Hardy won an interesting case last week involving the sleeping pill Ambien. More than a dozen folks from Shook Hardy subscribe to this blog. Yet none of those subscribers told us about the firm's victory! We...
Videos